Challenges in clinical diagnosis of Clade I Mpox: Highlighting the need for enhanced diagnostic approaches.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
24 Jun 2024
Historique:
received: 20 03 2024
accepted: 04 06 2024
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: aheadofprint

Résumé

Due to limited diagnostic capacity and availability of point-of-care tests, diagnosis of Clade I mpox in the geographical regions most affected is usually on clinical grounds. This may be complicated due to the similarity between mpox and varicella (chickenpox) lesions. Visual assessment of lesions is also used for determining clinical progress and to assess patient outcomes in clinical trials. However, there has been no investigation into whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate between Clade I mpox lesion stages. The objective of this study was to evaluate inter-rater reliability and agreement between clinicians assessing lesions in patients with Clade I mpox. We presented experienced clinicians with 17 images of Clade I mpox or varicella and asked them to independently indicate the most likely diagnosis-mpox or varicella-and to categorise the lesions according to their stage. When selecting the most likely diagnosis, accuracy varied across all images, the inter-rater reliability was poor (κ = 0.223; z = 10.1) and agreement was moderate (Po = 68%). When categorising lesions according to their type, if a single lesion type was present in the image, inter-rater reliability was moderate (κ = 0.671, z = 40.6) and agreement was good (Po = 78%), but when multiple lesion types were shown in an image, both inter-rater reliability (κ = 0.153, z = 10.5) and agreement (Po = 29%) decreased substantially. This study demonstrates that there are presently limitations in using visual assessment to diagnose Clade I mpox and evaluate lesion stage and treatment outcomes, which have an impact on clinical practice, public health and clinical trials. More robust indicators and tools are required to inform clinical, public-health, and research priorities, but these must be implementable in countries affected by mpox.

Sections du résumé

BACKGROUND BACKGROUND
Due to limited diagnostic capacity and availability of point-of-care tests, diagnosis of Clade I mpox in the geographical regions most affected is usually on clinical grounds. This may be complicated due to the similarity between mpox and varicella (chickenpox) lesions. Visual assessment of lesions is also used for determining clinical progress and to assess patient outcomes in clinical trials. However, there has been no investigation into whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate between Clade I mpox lesion stages.
METHODOLOGY/PRINCIPLE FINDINGS RESULTS
The objective of this study was to evaluate inter-rater reliability and agreement between clinicians assessing lesions in patients with Clade I mpox. We presented experienced clinicians with 17 images of Clade I mpox or varicella and asked them to independently indicate the most likely diagnosis-mpox or varicella-and to categorise the lesions according to their stage. When selecting the most likely diagnosis, accuracy varied across all images, the inter-rater reliability was poor (κ = 0.223; z = 10.1) and agreement was moderate (Po = 68%). When categorising lesions according to their type, if a single lesion type was present in the image, inter-rater reliability was moderate (κ = 0.671, z = 40.6) and agreement was good (Po = 78%), but when multiple lesion types were shown in an image, both inter-rater reliability (κ = 0.153, z = 10.5) and agreement (Po = 29%) decreased substantially.
CONCLUSIONS CONCLUSIONS
This study demonstrates that there are presently limitations in using visual assessment to diagnose Clade I mpox and evaluate lesion stage and treatment outcomes, which have an impact on clinical practice, public health and clinical trials. More robust indicators and tools are required to inform clinical, public-health, and research priorities, but these must be implementable in countries affected by mpox.

Identifiants

pubmed: 38913721
doi: 10.1371/journal.pntd.0012087
pii: PNTD-D-24-00420
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0012087

Informations de copyright

Copyright: © 2024 Bourner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Josephine Bourner (J)

ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Esteban Garcia-Gallo (E)

ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Festus Mbrenga (F)

Institut Pasteur de Bangui, Bangui, Central African Republic.

Yap Boum (Y)

Institut Pasteur de Bangui, Bangui, Central African Republic.

Emmanuel Nakouné (E)

Institut Pasteur de Bangui, Bangui, Central African Republic.

Amy Paterson (A)

ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Benjamin Jones (B)

ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Piero Olliaro (P)

ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Amanda Rojek (A)

ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Classifications MeSH